An isolated antibody or functional fragment thereof that binds to GD2, wherein said antibody or functional fragment thereof comprises a combination of heavy chain variable domain and light chain variable domain selected from the following combinations (i) to (viii): (i) the VH domain comprising VH CDR1, CDR2 and CDR3 according to residues 26-33, residues 51-58, and residues 97-109 of SEQ ID NO: 2, and the VL domain comprising VL CDR1, CDR2 and CDR3 according to residues 27-37, residues 55-57, and residues 94-102 of SEQ ID NO: 4; (ii) the VH domain comprising VH CDR1, CDR2 and CDR3 according to residues 26-33, residues 51-58, and residues 97-109 of SEQ ID NO: 6; and the VL domain comprising VL CDR1, CDR2 and CDR3 according to residues 27-37, residues 55-57, and residues 94-102 of SEQ ID NO: 8; (iii) the VH domain comprising VH CDR1, CDR2 and CDR3 according to residues 26-33, residues 51-58, and residues 97-108 of SEQ ID NO: 10, and the VL domain comprising VL CDR1, CDR2 and CDR3 according to residues 27-38, residues 56-58, and residues 95-103 of SEQ ID NO: 12; (iv) the VH domain comprising VH CDR1, CDR2 and CDR3 according to residues 26-33, residues 51-58, and residues 97-109 of SEQ ID NO: 26, and the VL domain comprising VL CDR1, CDR2 and CDR3 according to residues 27-37, residues 55-57, and residues 94-102 of SEQ ID NO: 28; (v) the VH domain comprising VH CDR1, CDR2 and CDR3 according to residues 26-33, residues 51-58, and residues 97-108 of SEQ ID NO: 30, and the VL domain comprising VL CDR1, CDR2 and CDR3 according to residues 27-37, residues 55-57, and residues 94-102 of SEQ ID NO: 32; (vi) the VH domain comprising VH CDR1, CDR2 and CDR3 according to residues 26-33, residues 51-58, and residues 97-110 of SEQ ID NO: 34, and the VL domain comprising VL CDR1, CDR2 and CDR3 according to residues 27-32, residues 50-52, and residues 89-97 of SEQ ID NO: 38; (vii) the VH domain comprising VH CDR1, CDR2 and CDR3 according to residues 26-33, residues 51-58, and residues 97-110 of SEQ ID NO: 36, and the VL domain comprising VL CDR1, CDR2 and CDR3 according to residues 27-32, residues 50-52, and residues 89-97 of SEQ ID NO: 38; and (viii) the VH domain comprising VH CDR1, CDR2 and CDR3 according to residues 26-33, residues 51-58, and residues 97-108 of SEQ ID NO: 40, and the VL domain comprising VL CDR1, CDR2 and CDR3 according to residues 27-38, residues 56-58, and residues 95-103 of SEQ ID NO: 42. (i) the VH domain comprising VH CDR1, CDR2 and CDR3 according to residues 26-33, residues 51-58, and residues 97-109 of SEQ ID NO: 2, and the VL domain comprising VL CDR1, CDR2 and CDR3 according to residues 27-37, residues 55-57, and residues 94-102 of SEQ ID NO: 4; (ii) the VH domain comprising VH CDR1, CDR2 and CDR3 according to residues 26-33, residues 51-58, and residues 97-109 of SEQ ID NO: 6; and the VL domain comprising VL CDR1, CDR2 and CDR3 according to residues 27-37, residues 55-57, and residues 94-102 of SEQ ID NO: 8; (iii) the VH domain comprising VH CDR1, CDR2 and CDR3 according to residues 26-33, residues 51-58, and residues 97-108 of SEQ ID NO: 10, and the VL domain comprising VL CDR1, CDR2 and CDR3 according to residues 27-38, residues 56-58, and residues 95-103 of SEQ ID NO: 12; (iv) the VH domain comprising VH CDR1, CDR2 and CDR3 according to residues 26-33, residues 51-58, and residues 97-109 of SEQ ID NO: 26, and the VL domain comprising VL CDR1, CDR2 and CDR3 according to residues 27-37, residues 55-57, and residues 94-102 of SEQ ID NO: 28; (v) the VH domain comprising VH CDR1, CDR2 and CDR3 according to residues 26-33, residues 51-58, and residues 97-108 of SEQ ID NO: 30, and the VL domain comprising VL CDR1, CDR2 and CDR3 according to residues 27-37, residues 55-57, and residues 94-102 of SEQ ID NO: 32; (vi) the VH domain comprising VH CDR1, CDR2 and CDR3 according to residues 26-33, residues 51-58, and residues 97-110 of SEQ ID NO: 34, and the VL domain comprising VL CDR1, CDR2 and CDR3 according to residues 27-32, residues 50-52, and residues 89-97 of SEQ ID NO: 38; (vii) the VH domain comprising VH CDR1, CDR2 and CDR3 according to residues 26-33, residues 51-58, and residues 97-110 of SEQ ID NO: 36, and the VL domain comprising VL CDR1, CDR2 and CDR3 according to residues 27-32, residues 50-52, and residues 89-97 of SEQ ID NO: 38; and (viii) the VH domain comprising VH CDR1, CDR2 and CDR3 according to residues 26-33, residues 51-58, and residues 97-108 of SEQ ID NO: 40, and the VL domain comprising VL CDR1, CDR2 and CDR3 according to residues 27-38, residues 56-58, and residues 95-103 of SEQ ID NO: 42.